Apellis Pharmaceuticals Inc (APLS)
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
📈 **POSITIVE** • Low confidence analysis (56%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (85%) **Content type:** Clinical